Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astellas Pharma has decided to license the exclusive developing and commercializing rights to Merck for its experimental intravenous formulation of vernakalant (vernakalant i.v.) in Canada, Mexico and the US.
Subscribe to our email newsletter
As per the terms of the deal, Astellas is eligible to get an undisclosed upfront payment from Merck along with development, regulatory and sales milestone.
Earlier, Cardiome Pharma has licensed Astellas US to develop and commercialize vernakalant i.v. in Canada, Mexico and the US in October 2003.
Presently, Vernakalant i.v. is approved in more than 10 European nations for rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm.
Merck Cardiovascular and Atherosclerosis Research franchise head, senior vice president Michael Mendelsohn said with this agreement, Merck has secured worldwide rights to vernakalant i.v.
Astellas president and CEO Masao Yoshida said in reviewing the priorities of our North American development programs, Astellas has decided to divest its rights for vernakalant to Merck.